Filing Flows

Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Next earnings date

Arcturus Therapeutics Holdings (ARCT) earnings: beat the estimate

Arcturus Therapeutics Holdings (ARCT) reported on Nov 5, 2026 and beat the EPS estimate: −$0.26 against −$0.68 (+61.8%). Revenue was $18.3M for Q3 2026, +7% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+61.8% vs estimate
Beat rate80%

The last report

Arcturus Therapeutics Holdings reported revenue of $18.3M for the third quarter 2026 (+7% Y/Y), net loss $7.4M: Collaboration Revenue $16.9M, Grant $1.4M. How it makes money → · Every quarter →

Arcturus Therapeutics Holdings: EPS against the estimate, last 5 reportsArcturus Therapeutics Holdings: EPS against the estimate, last 5 reportsEstimateReported−$0.80−$0.49Nov 25−$0.76−$1.03Mar 26−$1.01−$0.95May 26−$1.03−$0.84Aug 26−$0.68−$0.26Nov 26
Latest (Nov 26): Estimate −$0.68, Reported −$0.26.

Arcturus Therapeutics Holdings' latest quarter

Arcturus Therapeutics Holdings, Q3 2026: revenue $18.3M (+7% year over year), operating margin -50.2%, net loss $7.4M, operating cash flow −$6.9M. The chart follows the revenue to costs, profit and cash.

Questions

Did Arcturus Therapeutics Holdings beat earnings?

Arcturus Therapeutics Holdings (ARCT) reported on Nov 5, 2026 and beat the EPS estimate: −$0.26 against −$0.68 (+61.8%).

When does ARCT report earnings?

The next date is not set yet.

Does Arcturus Therapeutics Holdings usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.